Stocks
Jupiter Neurosciences, Inc.JUNS
NASDAQHealthcareBiotechnology$2.75
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative and metabolic diseases, with a lead product candidate targeting mitochondrial dysfunction. Its pipeline includes treatments for conditions such as Alzheimer's disease and rare metabolic disorders, and investors track the stock for its early-stage clinical catalysts and potential in the central nervous system space.
52W Range: $2.25-$135.75
Congressional Interest in Jupiter Neurosciences, Inc. (JUNS)
No congressional trades have been disclosed for Jupiter Neurosciences, Inc. (JUNS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading JUNS?
No congressional trades found for this stock.